Q3 2022 Oncolytics Biotech Inc Earnings Call Transcript
Good morning, and welcome to Oncolytics Biotech's Third Quarter 2020 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
Now I would like to turn the call over to Jon Patton, Director of Investor Relations and Communications. Please go ahead, sir.
Thank you, operator, and good morning, everyone. Earlier this morning, Oncolytics issued 2 press releases. One announcing interim results from the pancreatic cancer cohort of the company's Phase I/II GOBLET trial, and a second providing recent operational highlights and financial results for the third quarter of 2022. The announcements and highlights provided in these press releases will be the topics of today's call. A replay should be available on the Events and Presentations section of the Oncolytics website approximately 2 hours after its completion. After remarks from company management, we'll open the call for Q&A.
As a reminder, various remarks made
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |